

DAFTAR PUSTAKA

- Abukhader MM. The Effect of Route of Administration in Thymoquinone Toxicity in Male and Female Rats. *Indian Journal of Pharmaceutical Sciences*, 2012; 74 (3): 195-200.
- Adeghate E, Kalász H. Amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function. *Open Medicinal Chemistry Journal*, 2011; 5 (2): 78-81.
- Adi P. 2008. *Pengaruh Pemberian Tepung Bekicot Terhadap Kadar Total Protein Darah pada Rattus Novergicus Strain Wistar dengan Diet Non Protein*. Tugas Akhir. Tidak diterbitkan, Fakultas Kedokteran Universitas Brawijaya, Malang.
- Aggarwal BB, Kunnumakkara AB. 2009. *Molecular Targets and Therapeutic Uses of Spices: Modern Uses for Ancient Medicine*. World Scientific Publishing Co. Pte. Ltd, Singapura, p. 260.
- Aggarwal N, Shishu. Nutritional Disorders & Therapy A Review of Recent Investigations on Medicinal Herbs Possessing Anti-Diabetic Properties. *Journal Nutrition Disorders Therapy*, 2011; 1 (1): 1-10.
- Al-Attar AM, Al-Taisan WA. Preventive Effects of Black Seed (*Nigella Sativa*) Extract on Sprague Dawley Rats Exposed to Diazinon. *Australian Journal of Basic and Applied Sciences*, 2010; 4(5): 957-968.
- Alimohammadi S, Rahim H, Javad J, Danial K, Reza M, Maryam T, Farshid K, and Hamid A. Protective and antidiabetic effects of extract from *Nigella sativa* on blood glucose concentrations against streptozotocin (STZ)-induced diabetic in rats: an experimental study with histopathological evaluation. *Diagnostic pathology*, 2013; 8(1): 137.
- Almeida DATD, Camila PB, Ethel LBN, and Ana AHF. Evaluation of Lipid Profile and Oxidative Stress in STZ-Induced Rats Treated with Antioxidant Vitamin. *Brazilian Archives of Biology and Technology*, 2012; 55 (4): 527-536.
- American Diabetes Association (ADA), 2013. *Diabetes Basics*, (Online), (<http://www.diabetes.org/diabetes-basics/type-2/?loc=db-slabnavi>), diakses 21 November 2013).
- Andaloussi AB, Louis M, Tri V, Bouchra M, Padma M, Abdellatif S, and Pierre SH. The In Vivo Antidiabetic Activity of *Nigella sativa* Is Mediated through Activation of the AMPK Pathway and Increased Muscle GLUT4 Content. *Evidence-Based Complementary and Alternative Medicine*, 2011; 2011: 1-9.

- Andreolo NA, Elisvânia FDS, Marina RA, and Luiz RL. Rat's Age Versus Huma's Age: What Is The Relationship?. *Arquivos Brasileiros de Cirurgia Digestiva*, 2012; 25 (1): 49-51.
- Archer M, Carin S, and Gary O. 2013. *Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Drug Class Review*. Final Report. University of Utah College of Pharmacy, Salt Lake City.
- Badawi A, Amira K, Pierre H, David ECC, Bibiana GB, Ahmed ES, and Mohamed K. Type 2 diabetes mellitus and inflammation:Prospects for biomarkers of risk and nutritional intervention. *Dove Press Journal : Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, 2010; 3: 173-86.
- Baker IDI. 2011. *Diabetes and Your Health*. Baker IDI Heart and Diabetes Institute. Melbourne, Australia.
- Balakrishnan BR, Gupta P. Pharmacognostical and physicochemical evaluation of seeds of *Nigella sativa* Linn. with special reference to evaluation of seed oil. *International Journal of Drug Discovery & Herbal Research*, 2011; 1(3): 153-156.
- Bastaki, S. Review Diabetes Mellitus and Its Treatment. *International Journal Diabetes & Metabolism*, 2005; 13: 111 -134.
- Bryant NJ, Roland G, and David EJ. Regulated Transport of The Glucose Transporter GLUT4. *Nature reviews. Molecular cell biology*, 2002; 3(4): 267-77.
- Cahová MH, Vavřínková, and Kazdová. Glucose-fatty acid interaction in skeletal muscle and adipose tissue in insulin resistance. *Physiological research / Academia Scientiarum Bohemoslovaca*, 2007; 56 (1): 1-15.
- Chang CLT, Yenshou L, Arlene PB, Yi-Ching C, Shao-Chih C, and Wen-Chin Y. Herbal Therapies for Type 2 Diabetes Mellitus: Chemistry, Biology, and Potential Application of Selected Plants and Compounds. *Evidence-Based Complementary and Alternative Medicine*, 2013, 2013: 1-34.
- Cook, Christopher L., John T. Johnson, and William E. Wade. 2008. *Pharmacotherapy: Principles and Practice*, Edited by Marie AC, Barbara GW, Terry, LS, Patrick MM, Jill MK, John CR, Joseph TD, The McGraw-Hill Companies, Inc., USA, p. 643-666.
- Curtis, L., Triplitt, Charles A., Reasner., and William L. Isley 2008. *Pharmacotherapy: a Pathophysiologic Approach*, 7th Ed., Edited by Joseph T. Dipiro, Robert LT, Gary CY, Gary RM, Barbara GW, Micahel P, The McGraw-Hill Companies, Inc., USA, p. 1205-1241.
- Debas HT. 2004. *Gastrointestinal Surgery: Pathophysiology and Management*. Springer-Verlag New York, Inc., USA, p. 250.

- DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. *Medicinal Clinic of North America*, 2004; 88(4): 787-835.
- Departemen Kesehatan Republik Indonesia. 1989. *Materia Medika Indonesia*, Jilid V. Menteri Kesehatan. Jakarta.
- Federer W. 1991. *Statistic and Society: Data Collection and Interpretation*, 2nd Ed., Marcel Dekker, New York.
- Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. *Diabetes care*, 2011, 34(2): S279-S284.
- Gauguier D, Bihoreau MT, Picon L, and Ktorza A. Insulin secretion in adult rats after intrauterine exposure to mild hyperglycemia during late gestation. *Diabetes*, 1991, 40 (2): 109-114.
- Gilani AH, Khan MAU. A Review of Medicinal Uses and Pharmacological Activities of *Nigella sativa*. *Pakistan Journal of Biological Sciences*, 2004; 7 (4): 441-451.
- Handayani W , Ahmad R, dan Mohammad RI. Susu Kedelai Menurunkan Resistensi Insulin pada Model Diabetes Melitus Tipe 2. *Jurnal Kedokteran Brawijaya*, 2009, 25 (2): 60-66.
- Harzallah HJ, Rahma G, Wafa K, Aya M, Mohamed H and Touhami M. Thymoquinone, the *Nigella sativa* bioactive compound, prevents circulatory oxidative stress caused by 1,2-dimethylhydrazine in erythrocyte during colon postinitiation carcinogenesis. *Oxidative Medicine and Cellular Longevity*, 2012; 2012: 1-6.
- Henske JA, Griffith, and Fowler. Initiating and Titrating Insulin in Patients With Type 2 Diabetes. *Clinical Diabetes*, 2009; 27(2): 72-76.
- Herbst KL, Hirsch B. Insulin Strategies for Primary Care Providers. *Clinical Diabetes*, 2002; 20 (1): 11-17.
- International Diabetes Federation. 2012. *Global Guideline for Type 2 Diabetes*. Merck and Co., Inc., Brussel, p. 1-117.
- Inzucchi SE, Richard MB, John BB, Michaela D, Ele F, Michael N, Anne LP, Apostolos T, Richard W, David RM. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes care*, 2012; 35: 1364-1379.
- Jali MV, Sanjay K, Sujata MJ, Shivaraj G. Familial early onset of type-2 diabetes mellitus and its complications. *North American Journal of Medical Sciences*, 2009; 1(7): 377-380.

- Jones MC. Therapies for Diabetes: Pramlintide and Exenatide. *American Family Physician*, 2007; 75 (12): 1831-1835.
- Kola B, Ashley BG, and Márta K. The Role of AMP-Activated Protein Kinase in Obesity. *Frontiers of hormone research*, 2008; 36: 198-211.
- KPL. 2013. *Technical Guide for ELISA*. KPL Inc., USA, p. 1-42.
- Krook A, M Björnholm, D Galuska, XJ Jiang, R Fahlman, MG Myers, H Wallberg-Henriksson, and JR Zierath. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. *Diabetes*, 2000; 49 (2): 284-292.
- Kubaszek A, Pihlajamäki J, Komarovski V, Lindi V, Lindström J, Eriksson J, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, and Laakso M. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. (Abstract). *Diabetes*. 2003; 52 (7): 1872-1876.
- Lin Y, Sun Z. Current views on type 2 diabetes. *Journal of Endocrinology* , 2010; 204 (1): 1-11.
- Mansour MA, OT Ginawi, T El-Hadiyah, AS El-Khatib, and OA Al-Shabanah, HA Al-Sawaf. Effect of Volatile Oil Constituents of Nigella Sativa on Carbon Tetrachloride-Induced Hepatotoxicity in Mice: Evidence for Antioxidant Effects of Thymoquinone. *Research Communications in Molecular Pathology and Pharmacology*, 2001; 110 (3&4): 239-251.
- Marliana SD, Venty S, and Suyono. *Screening Fitokimia dan Analisis Kromatografi Lapis Tipis Komponen Kimia Buah Labu Siam (Sechium edule Jacq . Swartz.) dalam Ekstrak Etanol*. *Biofarmasi*, 2005; 3 (1): 26-31.
- Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. *American Family Physician*, 2004; 70 (3): 489-500.
- Musi N, Michael FH, Jonas N, Monika S, Peter B, Olav R, Gaochao Z, Joanne MW, Olle L, Suad E, David EM, Anders T, and Laurie J Goodyear. Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes. *Diabetes*, 2002; 51: 2074-2081.
- Nathan DM, John BB, Mayer BD, Ele F, Rury RH, Robert S, and Bernard Z. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes care*, 2009; 32 (1):193-203.

- Niewoehner CB. 2004. *Endocrine Pathophysiology*, 2nd Ed., Hayes Barton Press, USA.
- Nikzamir A, Alireza P, Alireza K, and Hashemi T. Expression of Glucose Transporter 4 (GLUT4) is Increased by Cinnamaldehyde in C2C12 Mouse Muscle Cells. *Iranian Red Crescent Medical Journal*, 2014; 16 (2): 10-14.
- Olson AL. Regulation of GLUT4 and Insulin-Dependent Glucose Flux. *Molecular Biology*, 2012; 2012.
- Paget G, Barnes J. Toxicity test. In: Laurence DR, Bacharach AL, editors. *Evaluation of Drug Activities: Pharmacometrics*. London, New York: Academic press; 1964. p. 161-2.
- Patidar D, Dwivedi SK. Diabetes Mellitus : An Update. *International Journal of Pharmaceutical & Research Sciences*, 2012; 1(4): 259-276.
- PERSAGI. 2005. *Daftar Komposisi Bahan Makanan*. Jakarta: PERSAGI.
- Rajsekhar S, Kuldeep B. Pharmacognosy and Pharmacology of *Nigella sativa*-A Review. *International Research Journal of Pharmacy*, 2011; 2(11): 36-39.
- Rehman AU, Muhammad AS, Suhel A. Effect of Exercise and Muscle Contraction on Insulin Action, Transportation and Sensitivity and Muscle Fibres in type II Diabetes Mellitus. *American Journal of Medicine and Medical Sciences*, 2012; 2(6): 131-135.
- Rhodes CJ, White MF. Molecular Insights Into Insulin Action and Secretion. *European Journal of Clinical Investigation*, 2002; 32 (3): 3–13.
- Ripsin CM, Helen K, and Randall JU. Management of blood glucose in type 2 diabetes mellitus. *American Family Physician*, 2009; 79 (1):29-36.
- Rodbard HW, Paul SJ, Jaime AD, Daniel E, Alan JG, George G, Yehuda H, Edward SH, Harold L, Philip L, Etie SM, and Stanley SS. AACE / ACE Consensus Statement Statement by an American Association of Clinical Endocrinologists / American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus : An Algorithm for Glycemic Control AACE / ACE Glycemic Control Algorithm Consensus Panel. *Endocrine Practice*, 2009; 15(6).
- Salama RHM. Clinical and Therapeutic Trials of *Nigella Sativa*. *TAF Preventive Medicine Bulletin*, 2010; 9(5): 513-522.
- Sengupta P. The Laboratory Rat: Relating Its Age With Human's. *International Journal of Preventive Medicine*, 2013; 4(6): 624-630.
- Shubrook J, Randall C, Aili G, dan Frank S. Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. *Clinical medicine insights. Endocrinology and diabetes*, 2011; 4: 1–12.

- Srinivasan K, B Viswanad, Lydia A, CL Kaul, and P Ramarao. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. *Pharmacological research: the official journal of the Italian Pharmacological Society*, 2005; 52 (4):313-20.
- Steinberg GR, Belinda JM, Bryce JWVD, Matthew JW, Andrew LC, Barbara CF, Sofianos A, Joseph P, Cem ZG, David C, Gökhan SH, Mark AF, Thomas WK, and Bruce EK. Tumor necrosis factor- α -induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. *Cell Metabolism*, 2006; 4, 465–474.
- Sulistiyoningrum E. Tinjauan Molekuler dan Aspek Klinis Resistensi Insulin. *Mandala of Health*, 2010, 4(2): 132-134.
- Swinnen SG, Joost BH, J Hans DV. Insulin therapy for type 2 diabetes. *Diabetes care*, 2009; 32 (2): S253-9.
- Thévenod F. Pathophysiology of Diabetes Mellitus Type 2: Roles of Obesity, Insulin Resistance and β -Cell Dysfunction. *Diabetes and Cancer. Epidemiological Evidence and Molecular Links*, 2008; 19: 1–18.
- Ventura-Sobrevilla J, VD Boone-Villa, CN Aguilar, R Román-Ramos, E Vega-Avila, E Campos-Sepúlveda, and F Alarcón-Aguilar. Effect of Proceedings of the Western Pharmacology Society dose and Administration of Streptozotocin on Blood Sugar in Male CD1 Mice. *Proceedings of the Western Pharmacology Society*, 2011; 54: 5-9.
- Wang HJ, Yuan XJ, Wan S, Jing N, Tao W, Yong JL, and Zheng WF. Low dose streptozocin (STZ) combined with high energy intake can effectively induce type 2 diabetes through altering the related gene expression. *Asia Pacific Journal of Clinical Nutrition*, 2007; 16 (1): 412-417.
- Wang Z, Jeffrey W, and Patrick C. Treating type 2 diabetes mellitus with traditional chinese and Indian medicinal herbs. *Evidence-Based Complementary and Alternative Medicine*, 2013; 2013.
- Wilson RD, Islam MS. Fructose-fed streptozotocin-injected rat: an alternative model for type 2 diabetes. *Pharmacological Reports*, 2012, 64: 129-139.
- World Health Organization, 2007. *Diabetes Fact Sheet No. 312*, (Online), (<http://www.who.int/mediacentre/factsheets/fs312/en/>, diakses 2 Februari 2013).